CervoMed is trading at $2.97 (up 6.5%) in pre-market, recovering part of last week’s steep biotech selloff as investors weigh recent clinical and regulatory milestones.
- The company recently completed enrollment in its Phase 2a neflamapimod trial for frontotemporal dementia, supporting ongoing momentum.
- Prior FDA alignment and a patent allowance regarding dementia with Lewy bodies have strengthened the program’s profile and intellectual property.
- With no fresh company-specific headlines today, the move likely reflects broader repositioning within a risk-on market environment.